TickerFacts.

HUTCHMED (China) Ltd (HCM): Cost of Revenue

Annual figures by period end, from SEC filings.

$336.35M
Year ended 2025-12-31
+2.6%
3-year compound annual growth
$384.45M2022-12-31: $311.10M2023-12-31: $384.45M2024-12-31: $348.88M2025-12-31: $336.35M$336.35M
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$336.35M-3.6%2026-03-05, From 2025-01-01
2024-12-31$348.88M-9.3%2026-03-05, From 2024-01-01
2023-12-31$384.45M+23.6%2026-03-05, From 2023-01-01
2022-12-31$311.10Mn/a2025-03-19, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
HUTCHMED (China) Ltd (HCM)2025-12-31$336.35M-3.6%
Organogenesis Holdings Inc. (ORGO)2024-12-31$115.74M+8.7%
BridgeBio Pharma, Inc. (BBIO)2025-12-31$20.96M+440.5%
Insmed Inc (INSM)2025-12-31$122.94M+43.4%
Opko Health, Inc. (OPK)2025-12-31$400.94M-18.9%
Travere Therapeutics, Inc. (TVTX)2025-12-31$10.34M+33.5%
TG Therapeutics, Inc. (TGTX)2025-12-31$100.71M+161.7%
Nature's Sunshine Products Inc (NATR)2025-12-31$132.42M+2.1%
Zai Lab Ltd (ZLAB)2025-12-31$190.52M+29.5%

Compare HCM, ORGO, BBIO, INSM side by side · Screen every company in Pharmaceutical Preparations ↗